Last reviewed · How we verify
Radiopharmaceutical 18F-Fluorocholine
18F-Fluorocholine is a radiopharmaceutical that accumulates in cells with high choline uptake, allowing for imaging of cancer cells.
18F-Fluorocholine is a radiopharmaceutical that accumulates in cells with high choline uptake, allowing for imaging of cancer cells. Used for Imaging of prostate cancer, breast cancer, and other choline-avid tumors.
At a glance
| Generic name | Radiopharmaceutical 18F-Fluorocholine |
|---|---|
| Also known as | 18F-Fluorocholine |
| Sponsor | ITEL Telecomunicazioni Srl |
| Drug class | Radiopharmaceutical |
| Target | Choline transporter |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This is achieved through the use of 18F-fluorocholine, a radiolabeled choline analog that is taken up by cells with high choline demand, such as cancer cells. The resulting images can help identify and stage cancer, as well as monitor treatment response.
Approved indications
- Imaging of prostate cancer, breast cancer, and other choline-avid tumors
Common side effects
- Radiation exposure
Key clinical trials
- Prospective Comparison of 18F-choline PET/CT and 18F-FDG PET/CT in the Initial Work-up of Multiple Myeloma (PHASE3)
- Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma (PHASE2)
- Prospective Comparative Study for Patients With Biochemical Recurrence Prostate Cancer Detecting by 18F-JK-PSMA-7 (PHASE3)
- Role of PET/CT With Fluorine-18 Tracers of Bone Metastases in Prostate Cancer
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: